江苏康众数字医疗科技股份有限公司 控股子公司管理制度 第一章 总则 第一条 为促进江苏康众数字医疗科技股份有限公司（以下简称"公司"或 "本公司"）规范运作和健康发展，确保控股子公司规范、高效、有序运作，提 高公司整体资产运营质量，维护公司整体形象和投资者利益，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》《上海证券交易 所科创板股票上市规则》等法律、法规、规范性文件以及《江苏康众数字医疗科 技股份有限公司章程》（以下简称"《公司章程》"）规定，结合公司实际情况，特 制定本制度。 第二条 本制度所称"控股子公司"系指本公司持有其 50%以上的股份，或者 虽然持有其股份比例不足 50%、但能够实际控制的公司。 第三条 加强对控股子公司的管理，旨在建立有效的管控与整合机制，对本 公司的组织、资源、资产、投资等事项进行风险控制，提高本公司整体运作效率 和抵抗风险能力。 第四条 公司应依照本制度及相关内控制度的规定，及时、有效地对控股子 公司做好管理、指导、监督等工作。 第五条 控股子公司在本公司总体方针目标框架下，独立经营和自主管理， 合法有效地运作企业资产。 第二章 人事管理 第 ...

证券代码：688607 证券简称：康众医疗 公告编号：2023-028 持股 5%以上股东减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，江苏康众数字医疗科技股份有限公司（以下简称"公 司"或"康众医疗"）股东畅城有限公司即 Matrix Future Limited（以下简称 "畅城"）持有康众医疗股份 8,239,476 股，占公司总股本的 9.35%；霍尔果斯 君联承宇创业投资有限公司（以下简称"君联承宇"）持有康众医疗股份 3,213,645 股，占公司总股本的 3.65%。畅城与君联承宇是一致行动人，所持股 份均为公司 IPO 前取得股份，该部分股份于 2022 年 2 月 7 日起限售期届满并上 市流通。 减持计划的进展情况 2023 年 4 月 18 日，公司披露了《康众医疗持股 5%以上股东减持股份计划公 告》（2023-007），畅城、君联承宇拟通过集中竞价及大宗交易方式合计减持不 超过 5,287,700 股（若计划 ...

Financial Performance - The company reported no cash dividends, stock bonuses, or capital reserve transfers for the 2022 profit distribution plan[5]. - The company has not achieved profitability since its listing[4]. - The company reported a revenue of ¥204,571,186.09 in 2022, a decrease of 40.18% compared to the previous year[21]. - The net profit attributable to shareholders was -¥5,623,874.72, down 106.61% year-on-year, while the net profit excluding non-recurring gains and losses was -¥21,196,323.74, a decline of 128.82%[23]. - The net cash flow from operating activities was -¥32,790,648.20, representing a 204.00% decrease from the previous year[24]. - Basic and diluted earnings per share were both -¥0.06, a drop of 106.06% compared to the previous year[24]. - The company achieved a main business revenue of 197,395,828.81 RMB, a year-on-year decrease of 39.83%, with medical revenue down 26.36% and industrial safety inspection revenue down 74.65%[104]. - The gross profit margin for the overall main business was 36.51%, a decrease of 11.30 percentage points compared to the previous year[106]. - Domestic revenue decreased by 35.29% to 96,597,020.60 RMB, while overseas revenue decreased by 43.61% to 100,798,808.21 RMB[106]. - The company's cash and cash equivalents decreased by 44.23%, amounting to ¥198,253,632.14 from ¥355,514,192.05 in the previous year[129]. Research and Development - The company increased its R&D investment to 21.76% of revenue, up 12.30 percentage points from the previous year[22]. - Research and development expenses for the year reached CNY 44,523,700, representing a year-on-year increase of 37.56%[34]. - The R&D team includes 4 PhD holders, 30 Master's degree holders, and 41 Bachelor's degree holders, reflecting a strong educational background[77]. - The company is focusing on developing an intelligent DRIC system, which includes real-time monitoring of X-ray source dosage and AI-assisted positioning, with plans for future investment in this technology[78]. - The company is actively developing new products, including wireless high-speed dynamic flat panel detectors and electronic materials for industrial applications, to enhance market presence[42]. - The company has developed a comprehensive range of digital X-ray flat panel detector products, covering major application areas including mammography, dynamic fluoroscopy, radiation therapy, and dental 3D imaging[82]. Market and Competition - The company faced intensified market competition and a decline in high-value product sales, impacting revenue and profitability[23]. - The company aims to enhance customer satisfaction by promoting a combination of flat panel detectors with key components such as tubes and high-voltage generators[35]. - The company is focusing on differentiated competition by investing in niche application areas of flat panel detectors, as the market concentration is expected to increase and competition intensifies[69]. - The global market for digital X-ray imaging systems is expected to expand significantly due to increasing replacement demand for outdated CR equipment and supportive national policies for DR technology development[65]. - The ongoing consolidation in the digital X-ray flat panel detector industry is expected to further increase market concentration, with major players accelerating mergers and acquisitions to enhance competitive advantages[67]. Governance and Management - The company received a standard unqualified audit report from its accounting firm[5]. - The company’s financial report is guaranteed to be true, accurate, and complete by its responsible personnel[5]. - The company’s board of directors and supervisory board members were all present at the board meeting[5]. - The company has established a governance structure that includes a strategic committee, nomination committee, compensation and assessment committee, and audit committee[155]. - The company emphasizes transparency and actively engages with investors, adhering to information disclosure obligations[159]. Strategic Initiatives - The company plans to enhance product competitiveness through increased R&D spending and operational management costs[23]. - The company aims to promote its global business strategy despite current market challenges[23]. - The company has established new subsidiaries in Singapore and South Korea, as well as an office in Europe, to enhance its international marketing and service network[36]. - The company is committed to cost optimization through various strategies, including enhancing production efficiency and upgrading core processes[38]. - The company plans to expand its overseas sales channels and improve service areas to increase market share in regions such as the US, India, and Europe[48]. Risks and Challenges - The company has detailed potential risks in its operations, which can be found in the "Management Discussion and Analysis" section[4]. - The company is subject to forward-looking statement risks, which do not constitute substantial commitments to investors[6]. - The company faces risks from reduced customer order demand and intensified market competition, impacting future performance[96]. - The company is exposed to foreign exchange risks due to its international operations, which could impact sales performance[98]. Employee and Compensation - The total number of employees in the parent company and major subsidiaries is 255, with 197 in the parent company and 58 in subsidiaries[189]. - The employee composition includes 73 production staff, 38 sales personnel, 78 technical staff, 15 finance staff, and 51 administrative staff[189]. - The company emphasizes a fair and performance-based compensation mechanism to motivate employees[190]. - Total compensation for all directors, supervisors, and senior management was RMB 4.3529 million at the end of the reporting period[175].

关于参加 2022 年度医疗设备专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688607 证券简称：康众医疗 公告编号：2023-024 江苏康众数字医疗科技股份有限公司 江苏康众数字医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了公司《2022 年年度报 告》，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况、 发展理念，公司参与了由上交所主办的 2022 年度医疗设备专场集体业绩说明会， 此次活动将采用视频和网络文字互动的方式举行，投资者可登录上海证券交易所 上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资者说明会以视频和网络文字互动形式召开，公司将针对 2022 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允 许的范围内就投资者普遍关注的问题进行回答。 二、说明会 ...

2022年年度报告 公司代码：688607 公司简称：康众医疗 江苏康众数字医疗科技股份有限公司 2022 年年度报告 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 50,118,994.79, representing a year-on-year increase of 31.58%[5] - The net profit attributable to shareholders was a loss of CNY 6,696,810.56, with a basic earnings per share of -0.08 yuan[5][6] - The company reported a net loss for Q1 2023, with total costs exceeding total revenue, indicating challenges in managing operational expenses[17] - The net profit for Q1 2023 was -6,670,634.06 RMB, compared to -7,232,998.53 RMB in Q1 2022, showing an improvement of approximately 7.8%[18] - The company reported a comprehensive loss of -7,755,168.80 RMB in Q1 2023, compared to -7,035,964.29 RMB in Q1 2022, indicating a decline of about 10.2%[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 900,801,285.14, a decrease of 0.21% compared to the end of the previous year[6] - Total assets amounted to RMB 900,801,285.14 as of March 31, 2023, slightly down from RMB 902,683,287.61 at the end of 2022[15] - Total liabilities increased to RMB 64,399,619.76 as of March 31, 2023, compared to RMB 58,526,453.43 at the end of 2022, reflecting an increase of 10.5%[16] - The company's equity attributable to shareholders decreased to RMB 836,421,291.38 as of March 31, 2023, down from RMB 844,202,636.68 at the end of 2022[16] Cash Flow - The company experienced a cash flow from operating activities loss of CNY 16,390,474.84[5] - Cash flow from operating activities showed a net outflow of -16,390,474.84 RMB in Q1 2023, an improvement from -18,775,283.32 RMB in Q1 2022[21] - The cash and cash equivalents at the end of Q1 2023 were 184,502,195.11 RMB, down from 216,869,303.99 RMB at the end of Q1 2022, a decrease of approximately 14.9%[23] - The investment activities resulted in a net cash outflow of -1,236,812.67 RMB in Q1 2023, compared to -118,933,422.09 RMB in Q1 2022, indicating a substantial reduction in cash outflow[23] Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 58,245,493.04, up from RMB 48,810,062.03 in Q1 2022, reflecting a year-over-year increase of 19.8%[17] - Research and development expenses totaled CNY 12,318,360.85, accounting for 24.58% of revenue, a decrease of 3.70 percentage points year-on-year[6] - Research and development expenses increased to 12,318,360.85 RMB in Q1 2023, up from 10,773,753.92 RMB in Q1 2022, reflecting a growth of approximately 14.3%[18] - The company incurred financial expenses of 1,236,356.97 RMB in Q1 2023, significantly higher than 88,717.06 RMB in Q1 2022, marking an increase of over 1,300%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,227[10] - Liu Jianqiang, an overseas natural person, held 14.54% of the shares, amounting to 12,810,000 shares[10] Strategic Focus - The company actively addressed internal and external uncertainties, leading to revenue growth through new products and technology implementations[8] - The company is focusing on expanding its market presence and enhancing product development to drive future growth[12]

证券代码：688607 证券简称：康众医疗 江苏康众数字医疗科技股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |------------|-----------------------------------------------------------------------------------------------------|-------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系 | □新闻发布会 □路演活动 | | | 活动类别 | □现场参观 ■一对一沟通 | | | | □其他 | | | | 2022 年 6 月 10 日： | | | | 华西证券自营 银华基金 | | | | 2022 年 6 月 16 日： | | | | 工银瑞信 | | | | 2022 年 6 月 17 日： | | | | 建信养老 | | | | 2022 年 6 月 20 日： 高毅资产 中融基金 鹏华基金 2022 年 6 月 21 日： 汇添富基金 | | | 参与单位 | 2022 ...

2022 年第三季度报告 证券代码：688607 证券简称：康众医疗 江苏康众数字医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 期增减变 | 年初至报告期 末 | 年初至报告期末比上年 同期增减变动幅度(%) | | --- | --- | --- | --- | --- | | | | 动幅度 | | | | | | (%) | | | | 营业收入 | 42,573,843.88 | -42.20 | 143,269,804.41 | -42.91 | | 归属于上市公司股 东的净利润 | -819,891.78 | -104.79 | -3,592,089.92 | -105.64 | 1 / 15 2022 年第三季度报告 | 归属 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[13]. - The company's operating revenue for the first half of 2022 was ¥100,695,960.53, a decrease of 43.20% compared to the same period last year[20]. - The net profit attributable to shareholders was -¥2,772,198.14, a significant decline from ¥46,517,819.95 in the previous year[22]. - The net cash flow from operating activities was -¥19,422,490.73, indicating a decrease due to reduced sales revenue[22]. - Basic earnings per share were -¥0.03, down from ¥0.55 in the same period last year[21]. - The total comprehensive income for the first half of 2022 was CNY -2.09 million, a significant decrease from CNY 46.17 million in the same period of 2021[175]. - The company reported a net loss of 110,000 RMB for the investment segment, with total revenue of 4,945,490 RMB, reflecting a growth rate of 5.61%[150]. - The company reported a financial expense of CNY -7.32 million in the first half of 2022, compared to CNY -1.30 million in the same period of 2021, indicating a significant increase in financial costs[174]. Research and Development - Research and development expenses increased by 30%, totaling RMB 15 million, to support innovation in medical imaging technology[13]. - Research and development expenses accounted for 22.26% of operating revenue, an increase of 14.92 percentage points year-on-year[21]. - The company reported a significant increase in R&D expenditures, totaling approximately ¥22.41 million in the current period compared to ¥13.01 million in the same period last year, with R&D expenses accounting for 22.26% of operating revenue[51]. - The number of R&D personnel increased to 83, representing 33.60% of the total workforce, up from 31.46% in the previous year[58]. - The R&D team is composed of highly qualified professionals, with 5 holding doctoral degrees and 33 holding master's degrees, enhancing the company's innovation capabilities[58]. - The company is focusing on the development of customized non-conventional flat panel detectors and advanced technologies such as CMOS sensors and IGZO applications[61]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[13]. - The company has established partnerships with three new distributors to enhance its sales network in the domestic market[13]. - The company is exploring market expansion opportunities, particularly in the investment management sector, to enhance revenue streams[150]. - The company plans to establish a wholly-owned subsidiary in Singapore with an investment of up to $15 million to enhance long-term strategic planning[93]. - The company is focused on optimizing its cost structure through various measures, including enhancing supply chain management and increasing automation levels[75]. Risks and Challenges - The management highlighted potential risks related to regulatory changes in the medical device industry, which could impact future operations[4]. - The company faces risks related to talent retention and potential core technology leaks, which could impact product development and operational performance[77][78]. - The company is expanding its overseas operations, establishing sales service centers in countries like the USA, India, and Japan, which may be affected by changes in market conditions and trade policies[79]. Product Development and Innovation - New product launches include an advanced digital X-ray imaging system, which is expected to enhance market competitiveness[13]. - The company is developing a new type of DR imaging system with a focus on optimizing resolution and achieving precise imaging[55]. - The company has launched new products in the fields of new energy battery testing and electronic testing, achieving full coverage of major application areas by the end of the reporting period[44]. - The company aims to enhance the portability of flat panel detectors through hardware and firmware restructuring[55]. - The company is focusing on market expansion through the introduction of innovative imaging technologies[55]. Financial Health and Assets - The company's total assets decreased by 5.00% to ¥894,043,385.88 compared to the end of the previous year[20]. - The net assets attributable to shareholders decreased by 3.17% to ¥843,255,568.31[20]. - Cash and cash equivalents decreased by 53.02% to ¥167,033,405.34, primarily due to reduced bank deposits[91]. - The total liabilities decreased to ¥50,795,804.49 from ¥70,164,253.35, indicating a reduction of about 27.5%[164]. - The company's total equity attributable to shareholders decreased to ¥843,255,568.31 from ¥870,901,046.65, reflecting a decline of approximately 3.2%[164]. Shareholder Commitments and Governance - The actual controller and shareholders of the company have committed to not transferring or entrusting the management of their shares for 36 months from the listing date[110]. - The company has established strict compliance with relevant laws and regulations regarding share transfers and commitments[111]. - The company emphasizes the importance of maintaining shareholder confidence through these commitments[110]. - The company will ensure clear control arrangements and stable operations during any share reduction process[113]. - The company will implement specific measures to stabilize its stock price if the closing price is below the audited net asset value per share for 20 consecutive trading days[113].

Financial Performance - The company's operating revenue for Q1 2022 was ¥38,090,182.58, representing a decrease of 57.09% compared to the same period last year[5]. - Total operating revenue for Q1 2022 was ¥38,090,182.58, a decrease of 57.0% compared to ¥88,763,204.08 in Q1 2021[21]. - Net profit for Q1 2022 was a loss of ¥7,232,998.53, compared to a profit of ¥22,426,173.56 in Q1 2021, representing a significant decline[22]. - The company reported a total comprehensive loss of ¥7,035,964.29 for Q1 2022, compared to a comprehensive income of ¥22,061,293.60 in Q1 2021[23]. - Basic and diluted earnings per share for Q1 2022 were both -¥0.08, compared to ¥0.28 in Q1 2021[23]. - Operating profit for Q1 2022 was ¥419,246.32, significantly down from ¥21,933,841.49 in Q1 2021[31]. - The net profit for Q1 2022 was a loss of ¥147,360.51, compared to a profit of ¥18,478,746.72 in Q1 2021[31]. Cash Flow and Investments - The net cash flow from operating activities was -¥18,775,283.32, primarily due to reduced revenue and increased R&D investments[10]. - The net cash flow from operating activities was -18,775,283.32 RMB, a significant decline compared to -4,232,062.58 RMB in the previous year, indicating a worsening operational cash flow situation[25]. - Cash received from sales of goods and services in Q1 2022 was ¥56,661,168.42, down 38.8% from ¥92,637,961.48 in Q1 2021[24]. - Total cash inflow from investment activities reached 786,814,946.45 RMB, a substantial increase from 256,050,152.64 RMB year-over-year, driven by other investment-related cash receipts of 783,396,660.00 RMB[25]. - The cash outflow for investment activities was 905,748,368.54 RMB, significantly higher than 307,815,110.11 RMB in the previous year, reflecting increased investment expenditures[25]. - The company reported a significant increase in investment activity cash inflow to ¥786,814,946.45 in Q1 2022, compared to ¥256,050,152.64 in Q1 2021[34]. - Total cash outflow from investment activities was ¥903,750,875.08 in Q1 2022, compared to ¥307,399,200.00 in Q1 2021[34]. Research and Development - Research and development expenses totaled ¥10,773,753.92, accounting for 28.28% of operating revenue, an increase of 21.22 percentage points year-on-year[6]. - Research and development expenses for Q1 2022 were ¥10,773,753.92, an increase of 72.5% from ¥6,262,597.54 in Q1 2021[21]. - Research and development expenses increased to ¥10,150,811.74 in Q1 2022, up 88.5% from ¥5,386,318.21 in Q1 2021[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥924,585,651.53, a decrease of 1.75% from the end of the previous year[6]. - The company's total assets amounted to RMB 924,585,651.53, a decrease from RMB 941,065,240.00 as of December 31, 2021, reflecting a decline of approximately 1.75%[16]. - The company's cash and cash equivalents were RMB 216,869,303.99, down from RMB 355,514,192.05, indicating a decrease of about 39.0%[16]. - Total liabilities as of Q1 2022 amounted to ¥59,176,234.81, a decrease from ¥70,164,253.35 in the previous year[19]. - The total liabilities decreased to 55,901,853.71 RMB from 65,182,854.84 RMB, showing a reduction in the company's debt levels[29]. - The company's total equity increased slightly to 851,473,124.06 RMB from 850,076,090.21 RMB, indicating stable shareholder value[29]. Shareholder Information - The company had a total of 6,252 common shareholders at the end of the reporting period[12]. - The top shareholder, LIU JIANQIANG, held 12,810,000 shares, representing 14.54% of the total shares[12]. Other Information - The company received government subsidies amounting to ¥229,511.33 during the reporting period[7]. - The company reported a non-recurring gain of ¥3,287,259.65 after tax, primarily from investment income[8]. - The company has not disclosed any new product or technology developments in this quarter[15]. - There are no significant mergers or acquisitions reported during this period[15].